1. Scrip
  2. >>Business
  3. >>Strategy

How The Curtain Finally Closed On Ferring/Blackstone’s Gene Therapy Venture FerGene

Back In Swiss Pharma’s Hands

 
• By Kevin Grogan

Having failed to live up to its promising beginnings, FerGene, the gene therapy firm founded with the backing of Ferring and Blackstone to advance the former’s candidate for bladder cancer is back under the Swiss pharma's wing. However, doubts about its future and that of nadofaragene firadonavec remain.

DNA
Ferring and Blackstone's gene therapy plans came unstuck • Source: Archive

Just shy of three years after Ferring Pharmaceuticals and Blackstone formed FerGene to advance the late-stage bladder cancer gene therapy nadofaragene firadenovec, the pharma company and the private equity firm have formally ended the collaboration, which has not been smooth.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.

Will China’s Retaliatory Tariffs Galvanize Manufacturing Onshoring?

 
• By Dexter Jie Yan

China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.

More from Business

Biotech Leaders Fear FDA Disruption Is Causing Delays

 
• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip

 
• By Mandy Jackson

Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.